IOL CHEMICALS AND PHARMACEUTICALS LIMITED Financials IOL Chemicals and Pharmaceuticals Limited NSE India S.E.
Equities
IOLCP
INE485C01011
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 376.2 INR | +0.60% |
|
+0.74% | -18.79% |
Valuation
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 16,608 | 21,965 | - | - |
| Enterprise Value (EV) 1 | 16,608 | 21,222 | 21,965 | 21,965 |
| P/E ratio | 11.9 x | 15.8 x | 10.4 x | 9.1 x |
| Yield | 1.41% | 1.7% | 0.96% | 2.02% |
| Capitalization / Revenue | 0.75 x | 1 x | 0.84 x | 0.79 x |
| EV / Revenue | 0.75 x | 1 x | 0.84 x | 0.79 x |
| EV / EBITDA | 7.36 x | 9.2 x | 6.4 x | 5.64 x |
| EV / FCF | -18.5 x | 13.6 x | 258 x | 22.6 x |
| FCF Yield | -5.39% | 7.33% | 0.39% | 4.43% |
| Price to Book | 1.1 x | 1.33 x | 1.22 x | 1.11 x |
| Nbr of stocks (in thousands) | 58,706 | 58,706 | - | - |
| Reference price 2 | 282.9 | 374.2 | 374.2 | 374.2 |
| Announcement Date | 4/28/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net sales 1 | 22,171 | 21,328 | 26,250 | 27,968 |
| EBITDA 1 | 2,257 | 2,306 | 3,433 | 3,892 |
| EBIT 1 | 2,051 | 1,677 | 2,653 | 3,222 |
| Operating Margin | 9.25% | 7.86% | 10.11% | 11.52% |
| Earnings before Tax (EBT) 1 | 1,886 | 1,816 | 2,822 | 3,218 |
| Net income 1 | 1,391 | 1,344 | 2,116 | 2,414 |
| Net margin | 6.28% | 6.3% | 8.06% | 8.63% |
| EPS 2 | 23.70 | 22.90 | 36.00 | 41.10 |
| Free Cash Flow 1 | -895.5 | 1,610 | 85 | 973 |
| FCF margin | -4.04% | 6.72% | 0.32% | 3.48% |
| FCF Conversion (EBITDA) | - | 53.49% | 2.48% | 25% |
| FCF Conversion (Net income) | - | 86.7% | 4.02% | 40.31% |
| Dividend per Share 2 | 4.000 | 6.350 | 3.600 | 7.550 |
| Announcement Date | 4/28/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 5,414 | 5,235 | 5,872 | 5,632 | 5,982 | 6,002 | 6,319 |
| EBITDA 1 | - | 426.9 | 953 | 725.2 | 849.5 | 770 | 778 |
| EBIT | - | - | - | - | - | - | - |
| Operating Margin | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income 1 | - | 237.9 | 647.8 | 458.6 | 547 | 484 | 494 |
| Net margin | - | 4.54% | 11.03% | 8.14% | 9.14% | 8.06% | 7.82% |
| EPS | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 2/7/23 | 4/28/23 | 8/9/23 | - | - | - |
1INR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow 1 | -896 | 1,610 | 85 | 973 |
| ROE (net income / shareholders' equity) | 9.6% | 11.8% | 12.4% | 12.8% |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets 1 | - | - | - | - |
| Book Value Per Share 2 | 257.0 | 282.0 | 307.0 | 338.0 |
| Cash Flow per Share | - | - | - | - |
| Capex 1 | 2,118 | 2,000 | 1,250 | 1,725 |
| Capex / Sales | 9.55% | 8.35% | 4.76% | 6.17% |
| Announcement Date | 4/28/23 | 5/14/24 | - | - |
1INR in Million2INR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
374.2
INR
Average target price
501.5
INR
Spread / Average Target
+34.04%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- IOLCP Stock
- IOLCP Stock
- Financials IOL Chemicals and Pharmaceuticals Limited
